GURE [GULF RESOURCES] UPLOAD: (Original Filing)
[]
[Company Contact China Biologic Products Reports Results for the Year 2011 Beijing, China, March 12, 2012 China Biologic Products, Inc. (NASDAQ: CBPO) (China Biologic or the Company), one of the leading plasma-based biopharmaceutical companies in the Peoples Republic of China (PRC), today reported its financial results for the year ended December 31, 2011. Financial highlights for the year 2011] [FORM 8-K CURRENT REPORT Date of Report (Date of Earliest event Reported): March 12, 2012 CHINA BIOLOGIC PRODUCTS, INC. Delaware 001-34566 75-2308816 (State or other jurisdiction of (Commission File No.) (IRS Employer ID No.) incorporation or organization) No. 14 East Hushan Road, Tai'an City, Shandong, 271000 People's Republic of China 86-538 -620-2306 ____________________________________________________________ (Former name or former address, if changed]
[FORM 10-K (Mark One) December 31, 2011 Commission File No. 001-34566 CHINA BIOLOGIC PRODUCTS, INC. Delaware 75-2308816 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 18th Floor, Jialong International Building, 19 Chaoyang Park Road (+86) 10-6598-3111 Title of each class Name of each exchange on which registered Common Stock, par value $0.0001 per share NASDAQ Global] [The Board of Directors We consent to the incorporation by reference in the registration statement (No. 333-171069) on Form S-3 and the registration statement (No. 333-151263) on Form S-8 of China Biologic Products, Inc. of our reports dated March 12, 2012, with respect to the consolidated balance sheets of China Biologic Products, Inc. and subsidiaries as of December 31, 2011] [Consent of Independent Registered Public Accounting Firm To the Board of Directors of We consent to the use of our report dated March 23, 2010, except for the effects on the consolidated financial statements of the restatement described in Note 2, as to which the date is March 31, 2011, with respect to the consolidated balance sheets of China Biologic] [CERTIFICATIONS I, Chao Ming Zhao, certify that: 1. I have reviewed this annual report on Form 10-K of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATIONS I, Yu-Yun Tristan Kuo, certify that: 1. I have reviewed this annual report on Form 10-K of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. th] [2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. th (Principal Financial and Accounting Officer)]
[March 2012 3 Investment Highlights Rapidly growing & profitable diversified paper products manufacturer and distributor in northern China Government - mandated industry consolidation eliminates smaller competitors Strategically located in Beijing/Tianjin, China’s printing/publishing hub Strategic location creates cost advantage and strong supplier relationships Compelling growth strategy to expand future production capacity with internal cash flow and debt financing 4 Equity Snapshot] []
[March 2012 3 Investment Highlights Rapidly growing & profitable diversified paper products manufacturer and distributor in northern China Government - mandated industry consolidation eliminates smaller competitors Strategically located in Beijing/Tianjin, China’s printing/publishing hub Strategic location creates cost advantage and strong supplier relationships Compelling growth strategy to expand future production capacity with internal cash flow and debt financing 4 Equity Snapshot] []
[Item 1: Reporting Person - FMR LLC Item 4: Delaware Item 5: 5,200 Item 6: 0 Item 7: 418,926 Item 8: 0 Item 9: 418,926 Item 11: 0.118% Item 12: HC Cusip #Y3197V101 Item 1: Reporting Person - Edward C. Johnson 3d Item 5: 0 Item 6: 0 Item 7: 418,926 Item 8: 0 Item 9: 418,926 Item 11: 0.118%]
[Item 1: Reporting Person - FMR LLC Item 4: Delaware Item 5: 5,200 Item 6: 0 Item 7: 418,926 Item 8: 0 Item 9: 418,926 Item 11: 0.118% Item 12: HC Cusip #Y3197V101 Item 1: Reporting Person - Edward C. Johnson 3d Item 5: 0 Item 6: 0 Item 7: 418,926 Item 8: 0 Item 9: 418,926 Item 11: 0.118%]
[1. NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Janus Capital Management LLC EIN #75-3019302 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP a. ___ b. _X_ 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: 5. SOLE VOTING POWER 8,789,674**]
[1. NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Janus Capital Management LLC EIN #75-3019302 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP a. ___ b. _X_ 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: 5. SOLE VOTING POWER 8,789,674**]